MediPharm Labs Corp. MEDIF
OTC PK
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 10.40% | -17.66% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 10.40% | -17.66% | |||
| Cost of Revenue | -2.59% | -20.86% | |||
| Gross Profit | 32.58% | -11.55% | |||
| SG&A Expenses | 1.21% | -0.19% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -5,200.00% | -100.58% | |||
| Total Operating Expenses | -1.44% | -15.88% | |||
| Operating Income | 108.17% | -4.47% | |||
| Income Before Tax | 100.46% | 55.23% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 100.46% | 55.23% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 100.46% | 55.23% | |||
| EBIT | 108.17% | -4.47% | |||
| EBITDA | 173.09% | -8.82% | |||
| EPS Basic | 100.00% | 54.55% | |||
| Normalized Basic EPS | 111.11% | 10.00% | |||
| EPS Diluted | 100.00% | 54.55% | |||
| Normalized Diluted EPS | 111.11% | 10.00% | |||
| Average Basic Shares Outstanding | 0.16% | 0.75% | |||
| Average Diluted Shares Outstanding | 0.16% | 0.75% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||